Phaseline

Companies › Juventas Cell Therapy

Juventas Cell Therapy: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 3 Phase 2, 3 Phase 1; Oncology, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CNCT19
anti-CD19 CAR-T cell therapy
CD19Phase 2Non-Hodgkin's Lymphoma; Relapsed or Refractory Acute Lymphoblastic Leukemia; B-cell Acute Lymphoblastic LeukemiaDec 2026
Inaticabtagene autoleucel Injection
CD19-directed CAR-T cells (autologous 2nd generation)
–Phase 1Autoimmune Thrombocytopenia; B-cell Acute Lymphoblastic LeukemiaDec 2027
HY001N Cell Injection
CAR-T cell therapy
–Phase 1Autoimmune Hemolytic Anemia (AIHA)Sep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04586478CNCT19Phase 2Non-Hodgkin's LymphomaOncologyMar 2024
NCT04684147CNCT19Phase 2Relapsed or Refractory Acute Lymphoblastic LeukemiaOncologyDec 2026
NCT05667506CNCT19Phase 1B-cell Acute Lymphoblastic LeukemiaOncologyMay 2027
NCT06826430Inaticabtagene autoleucel InjectionPhase 1Autoimmune ThrombocytopeniaHematologyDec 2027
NCT06608732Inaticabtagene autoleucel InjectionPhase 2B-cell Acute Lymphoblastic LeukemiaOncologyJul 2028
NCT07748533HY001N Cell InjectionPhase 1Autoimmune Hemolytic Anemia (AIHA)HematologySep 2028

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Beijing Yongtai Ruike Biotechnology Company iCell Gene Therapeutics Grit Biotechnology Shanghai Ming Ju Biotechnology PersonGen BioTherapeutics (Suzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.